Alimera Announces Multiple Abstracts Highlighting ILUVIEN Real-World Data at EURETINA Annual Congress

Alimera Sciences announced that clinical data for ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022.

Audio Narration Free Papers:

• Bernardete Pessoa, MD, PhD et al. RIVER Study – first registry data on the use of ILUVIEN® (0.19 mg Fluocinolone acetonide implant, FAc) in Portugal
• Susana Penas, MD et al. Real-world outcomes of intravitreal fluocinolone acetonide implant for the treatment of recurrent and persistent diabetic macular edema in Portugal – results from the RIVER study based on baseline visual acuity
• Lilianne Duarte, MD et al. Clinical course, safety and efficacy after 48 months of first ILUVIEN® (fluocinolone acetonide, FAc, 0.2μg/day) implant in eyes with recurrent and persistent Diabetic Macular Edema. A multicenter study
• Ramin Khoramnia, MD et al. Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study
• João Ramalhão, MD et al. Fluocinolone acetonide implant 0.19 mg (ILUVIEN®) in the treatment of diabetic macular edema: 48-month follow up
• Michael Singer, MD et al. 3-Year Safety and Functional Outcomes in DME Patients treated with the 0.19 mg FAc Implant in the Phase IV, Prospective PALADIN Study.
• Veeral Sheth, MD et al. Three Year Outcomes from the PALADIN Phase IV Study: A Comparison of Anatomical Metrics Pre- and Post-FAc Treatment and their Relationship to Efficacy and Treatment Burden Outcomes
• João Romano, MD et al. Retreatment with fluocinolone acetonide intravitreal implant: effectiveness and safety outcomes from patients with diabetic macular edema treated with the long-acting corticosteroid implant
• Filipa Madeira, MD et al. Long term real-world effectiveness and safety study of fluocinolone acetonide intravitreal implant in patients with persistent diabetic macular edema: a single center analysis
• Francisca Bragança, MD et al. ILUVIEN® (fluocinolone acetonide 0.19 mg, FAc) in recurrent and persistent diabetic macular edema: effectiveness and safety outcomes comparison between monotherapy and in combination with adjuvant therapy
• Vitor Miranda, MD et al. OCT biomarkers changes in response to Dexamethasone implant for treating Diabetic Macular Edema and Retinal Vein Occlusion Edema

On-Demand Poster:

• Mario Canastro, MD et al. Fluocinolone acetonide intravitreal implant, the long-acting corticosteroid, for the treatment of patients with diabetic macular edema: retrospective single center study